Family Med Medical News about methamphetamine clinical pharmacology

Become a Member Today!
Register

Most Viewed Abstracts

1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

2. Omega-3 fatty acids for bipolar disorder

3. Is folic acid good for everyone

4. ACS Releases Guidelines for HPV Vaccination

5. Vitamin D - A review Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A review of the clinical pharmacology of methamphetamine
Addiction, 06/29/09

Cruickshank CC et al. - Repeated use may induce neurotoxicity, associated with prolonged psychiatric symptoms, cognitive impairment and an increased risk of developing Parkinson's disease. Abrupt cessation of repeated methamphetamine use leads to a withdrawal syndrome consisting of depressed mood, anxiety and sleep disturbance.

Methods

Relevant literature was identified through a PubMed search.
Additional literature was obtained from relevant books and monographs.

Results

The mean elimination half-life for methamphetamine is approximately 10 hours, with considerable inter-individual variability in pharmacokinetics.
Direct effects at low-to-moderate methamphetamine doses (5-30 mg) include arousal, positive mood, cardiac stimulation and acute improvement in cognitive domains such as attention and psychomotor coordination.
At higher doses used typically by illicit users (≥50 mg), methamphetamine can produce psychosis.
Its hypertensive effect can produce a number of acute and chronic cardiovascular complications.
Acute withdrawal lasts typically for 7-10 days, and residual symptoms associated with neurotoxicity may persist for several months.

<< Previous
Disease-Specific, Versus Standard, Nutritional Support for the...

Next >>
Transfer of occupational health problems from a developed to a...